HAYWARD, Calif., May 16, 2013 /PRNewswire/ -- Scientists at the Center for Learning and Memory, Tsinghua University, Beijing, and the California-based biopharmaceutical company Magceutics, Inc. (www.magceutics.com) have demonstrated a novel therapy for reversing memory decline in mice with Alzheimer's Disease. By increasing brain magnesium levels, they find significant cognitive improvement in advanced stage AD mice. The study is the first to demonstrate a mechanism for reversing cognitive decline for advanced stage AD mice, and is also the first to show an effective long term treatment for early stage AD mice.
"We found that the elevation of brain magnesium can prevent cognitive decline in Alzheimer's Disease model mice," explained Magceutics founder Guosong Liu , a professor at Tsinghua University and senior investigator on the study. The report, which appeared online May 8th in the Journal of Neuroscience, shows that a newly developed magnesium compound known as Magtein™ (Magnesium-L Threonate) can prevent cognitive impairment when administered to mice with early stage AD. The treatment was shown to remain effective for at least 16 months. Additionally, Magtein significantly improved memory and cognition when given to advanced stage AD mice.
Liu and colleagues believe that because the loss of neuronal connections in brain regions critical for memory function is major hallmark of Alzheimer's Disease, preventing those losses can lead to new treatment options. In earlier studies, they determined the principle for controlling the density and plasticity of connections (synapses) between neurons in the hippocampus, the brain region that processes memory. Those studies revealed that the elevation of brain magnesium can selectively reduce background calcium within synapses and thereby enhance sy
|SOURCE Magceutics, Inc.|
Copyright©2012 PR Newswire.
All rights reserved